IBRX Stock Rout Deepens: Founder Points To Cancer-Fighting Cell Bank Data As Investors Look For Catalyst The project relies on an AI-driven manufacturing robot, Leonardo, to automate production and potentially scale NK cell output.
IBRX Stock Declines Pre-Market — ImmunityBio Resubmits Anktiva Application To FDA With Additional Data ImmunityBio stated that the application includes additional information requested by the FDA to support its supplemental BLA for papillary disease.
Can IBRX Stock Snap Its 4-Day Slide? Founder Promises ‘Game-Changer’ Anktiva Data As FDA Speeds Drug Reviews The founder cited remarks from a former FDA official and an NIH Director supporting mechanism-based review to speed patient access to therapies like Anktiva.
IBRX Founder’s ‘Congrats’ To GSK Sparks Debate After FDA Fast Drug Approvals — Retail Slams Big Pharma Bias Over Anktiva Investors are focused on Anktiva’s next regulatory step, as ImmunityBio seeks to expand the therapy to BCG-unresponsive papillary bladder cancer.
Forget ImmunityBio: This Big‑Cap Pharma Is the Safer Play on Next‑Gen Cancer Therapies Merck can help stabilize investors' portfolios, whereas ImmunityBio would be a source of volatility.
IBRX Vs IOVA: Which Cancer Immunotherapy Stock Has Bigger Breakout Ahead? Investors are increasingly comparing ImmunityBio and Iovance Biotherapeutics as both cancer drug developers move into catalyst-heavy phases.
ImmunityBio (IBRX) Shares Plummet Despite Piper Sandler Price Target Hike and 700% Revenue Growth In a classic case of "selling the news," shares of ImmunityBio, Inc. (
NASDAQ: IBRX ) took a sharp dive on Wednesday, March 4, 2026, plummeting over 13% to close at $9.02. The sell-off came as a surprise to many retail investors, especially considering that the drop coincided with a significant
IBRX Stock Tumbles After-Hours: Flags ‘Terrible’ BCG Shortage As Saudi Anktiva Launch Nears Amid Middle East Tensions To address the BCG shortage, ImmunityBio highlighted its recombinant BCG program, with 580 patients enrolled across about 100 clinical sites.
IBRX Stock Eyes Green Open Ahead Of Earnings — What Happened With Anktiva Over The Weekend Founder Patrick Soon-Shiong spotlighted Anktiva on national TV, emphasizing IL-15’s potential to activate the immune system and its combination approach with Merck’s Keytruda.
IBRX Stock Rallies Into Trump’s Big SOTU Night — Here’s What Traders Think Could Fuel The Next Move Traders debated whether Trump could reference cancer priorities or FDA reform, with some betting a mention could spark another leg higher for IBRX.
IBRX Stock Surges Past 4-Year Highs: Analyst Sees over 50% Upside After Anktiva’s Blowout Growth ImmunityBio outlined a three-year plan to position Anktiva as a backbone immunotherapy, advancing more than 30 trials across 10 tumor types.
Stock Market Today, Feb. 23: ImmunityBio Surges After Anktiva Revenue Jumps 700% On Feb. 23, 2026, investors weighed ANKTIVA’s explosive revenue ramp against ImmunityBio’s deep losses and ambitious global expansion.
Why ImmunityBio Stock Is Soaring Again Today ImmunityBio's stock has roughly quintupled so far in 2026 as the company continues to deliver good news for investors.
ImmunityBio’s Q4 Revenue Gets A Lift From ANKTIVA Sales – IBRX Stock Gains 1% Pre-Market Net product revenue in the fourth quarter surged 431% to $38.3 million, above estimates of $37.8 million, according to Fiscal.ai data
